Literature DB >> 1382832

Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers.

D P Wood1, H W Herr, R J Motzer, V Reuter, P C Sogani, M J Morse, G J Bosl.   

Abstract

BACKGROUND: Chemorefractory metastatic germ cell tumors and elevated tumor markers generally indicate inoperable disease.
METHODS: Solitary metastases were resected in 15 patients who had a nonseminomatous germ cell tumor and an elevated alpha-fetoprotein (AFP) and/or human chorionic gonadotropin (HCG) serum level after treatment with cisplatin-based chemotherapy. Patients underwent resection for a residual mass after chemotherapy or for a new solitary metastasis after achieving a complete response (CR) to salvage chemotherapy.
RESULTS: Seven patients were disease-free after surgical resection alone. All five patients with an elevated HCG level had a relapse after surgery compared with 3 of 10 patients with only an elevated AFP level. Only 4 of 10 patients with a retroperitoneal metastasis had a relapse after surgery compared with 4 of 5 patients with visceral disease. Eleven of 15 patients overall were disease-free after surgery and subsequent chemotherapy after a relapse.
CONCLUSIONS: Surgical resection of a solitary metastasis despite elevated serum tumor markers should be considered in patients who have not had a durable CR to cisplatin-based chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1382832     DOI: 10.1002/1097-0142(19921101)70:9<2354::aid-cncr2820700924>3.0.co;2-u

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

Review 1.  Retroperitoneal lymph node dissection: an update in testicular malignancies.

Authors:  K Yadav
Journal:  Clin Transl Oncol       Date:  2017-02-01       Impact factor: 3.405

2.  Surgical resection should be viewed with skepticism in patients with bladder cancer.

Authors:  Thomas Otto
Journal:  Dtsch Arztebl Int       Date:  2013-03-08       Impact factor: 5.594

Review 3.  A review of second-line chemotherapy and prognostic models for disseminated germ cell tumors.

Authors:  Martin H Voss; Darren R Feldman; George J Bosl; Robert J Motzer
Journal:  Hematol Oncol Clin North Am       Date:  2011-04-22       Impact factor: 3.722

Review 4.  Surgical salvage in patients with advanced testicular cancer: indications, risks and outcomes.

Authors:  Ryan W Speir; Clint Cary; Timothy A Masterson
Journal:  Transl Androl Urol       Date:  2020-01

Review 5.  Current Management of Refractory Germ Cell Tumors and Future Directions.

Authors:  J Clayton Allen; Austin Kirschner; Kristen R Scarpato; Alicia K Morgans
Journal:  Curr Oncol Rep       Date:  2017-02       Impact factor: 5.075

Review 6.  Diagnosis and treatment of patients with testicular germ cell cancer.

Authors:  J T Hartmann; L Kanz; C Bokemeyer
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

7.  Results of salvage retroperitoneal lymphadenectomy (RLA) in the treatment of patients with nonseminomatous germ cell tumours remaining marker positive after inductive chemotherapy.

Authors:  L Kisbenedek; I Bodrogi; P Szeldeli; M Baki; P Tenke; J Horti
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

8.  Management of poor-prognosis testicular germ cell tumors.

Authors:  Kiranpreet Khurana; Timothy D Gilligan; Andrew J Stephenson
Journal:  Indian J Urol       Date:  2010 Jan-Mar

9.  Successful 2-year-long remission following repeated salvage surgery in a patient with chemotherapy-resistant metastatic nonseminomatous germ cell tumor.

Authors:  Hideki Takeshita; Junji Yonese; Yasuhisa Fujii; Satoru Kawakami; Yoshinobu Komai; Yuhei Ohkubo; Shinya Yamamoto; Yuichi Ishikawa; Yasuyuki Seto; Shigekazu Ohyama; Iwao Fukui
Journal:  Int J Clin Oncol       Date:  2007-12-21       Impact factor: 3.402

10.  Size and status of metastases after inductive chemotherapy of germ-cell tumors. Indication for salvage operation.

Authors:  N Jaeger; L Weissbach; R Bussar-Maatz
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.